S'abonner

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration - 03/02/26

Doi : 10.1016/S1470-2045(25)00658-8 
Chad Tang, MD a, ⁎ , Alex D Sherry, MD a, j, Hyunsoo Hwang, PhD b, David P Farris, MSIS c, Giulio Francolini, MD f, Vanessa Di Cataldo, MD f, Lorenzo Livi, MD f, Phuoc Tran, ProfMD PhD a, g, h, Paul G Corn, ProfMD PhD d, Ana Aparicio, ProfMD d, Gabriele Simontacchi, MD f, Ana P Kiess, MD PhD h, Jarey H Wang, MD PhD h, Valerie Fonteyne, MD PhD i, Renee Bultijnck, MD i, Ryan Phillips, MD j, Matthew P Deek, MD k, Robert Olson, ProfMD l, Stephen Harrow, MD m, Giulia Marvaso, MD n, o, Chiara Lorubbio, MD o, Barbara A Jereczek-Fossa, ProfMD PhD n, o, Ethan B Ludmir, MD e, Pierre Blanchard, ProfMD PhD p, Andrew Warner, MSc q, Ryan Sun, PhD b, David A Palma, ProfMD PhD q, Piet Ost, MD PhD i, r
a Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 
b Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 
c Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 
d Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 
e Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 
f Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence University, Firenze, Italy 
g Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA 
h Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA 
i Department of Human Structure and Repair, Ghent University, Belgium 
j Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA 
k Department of Radiation Oncology, Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA 
l Division of Radiation Oncology, University of British Columbia, Vancouver, BC, Canada 
m Department of Clinical Oncology, Beatson West of Scotland Cancer Center, Glasgow, UK 
n Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy 
o Department of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy 
p Department of Radiation Oncology, Gustave Roussy Cancer Campus, INSERM 1018 CESP, University Paris-Saclay, Villejuif, France 
q Division of Radiation Oncology, Department of Oncology, Western University and London Health Sciences Centre, London, ON, Canada 
r Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium 

* Correspondence to: Dr Chad Tang, Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030–3721, USA Department of Genitourinary Radiation Oncology The University of Texas MD Anderson Cancer Center Houston TX 77030–3721 USA

Summary

Background

Oligometastatic disease represents the proximal end of a metastatic spectrum. Metastasis-directed therapy (MDT) is increasingly used to treat oligometastatic disease despite the absence of level 1 evidence. We amalgamated individual patient data across trials to evaluate the effectiveness of MDT for oligometastatic prostate cancer.

Methods

We conducted a systematic review and individual patient data meta-analysis. We systematically searched Embase, PubMed, CENTRAL, MEDLINE, and ClinicalTrials.gov to identify randomised trials of MDT enrolling patients with oligometastatic prostate cancer. Inclusion criteria were published randomised prospective trials enrolling patients with oligometastatic (up to five metastases) prostate cancer, in which investigators recorded sufficient data to evaluate progression-free survival and overall survival. This systematic review was conducted from database creation to Nov 3, 2023, and was updated on May 4, 2025. Data appraisal was conducted using Covidence with two investigators (CT and ADS) performing independent screens. Studies were evaluated using the Cochrane Collaboration ’ s risk-of-bias assessment (version 2.0). Individual patient data were provided by investigators. Coprimary endpoints were progression-free survival and overall survival. Secondary endpoints were radiographic progression-free survival and castration resistance-free survival. The primary analysis was conducted in the subset of studies in which patients were randomly assigned to MDT plus standard of care (SOC) versus SOC. The primary analysis included a trial-level analysis using a random effects model and a patient-level analysis stratifying by trial. This meta-analysis is registered with PROSPERO (CRD42023479078).

Findings

Of 2975 studies identified for screening, seven phase 2 studies randomly assigning 574 men were included. Six trials randomly assigning 472 patients to MDT plus SOC (n=248) versus SOC (n=224) were used to evaluate MDT and had a median follow-up time of 40·7 months (IQR 25·6–53·7). MDT was associated with improved progression-free survival (trial-level hazard ratio [HR] 0·44, [95% CI 0·35–0·56], p<0·0001; patient-level HR 0·45 [0·35–0·57], p<0·0001), radiographic progression-free survival (trial-level HR 0·60 [0·42–0·85], p=0·0039; patient-level HR 0·59 [0·46–0·76], p<0·0001), and castration resistance-free survival (trial-level HR 0·58 [95% CI 0·37–0·92], p=0·019; patient-level HR 0·58 [95% CI 0·37–0·91], p=0·017). The association between MDT and overall survival showed an HR of 0·63 (95% CI 0·39–1·00, p=0·051) in trial-level analyses and 0·64 (95% CI 0·40–1·01, p=0·057) in patient-level analyses.

Interpretation

WOLVERINE showed a benefit with MDT for oligometastatic prostate cancer in progression-free survival, radiological progression-free survival, and castration resistance-free survival. Overall survival benefit was not significant and further research is needed.

Funding

Philanthropic gift and National Cancer Institute.

Le texte complet de cet article est disponible en PDF.

Plan


© 2026  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 27 - N° 2

P. 181-190 - février 2026 Retour au numéro
Article précédent Article précédent
  • O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial
  • Anca-Ligia Grosu, Wolfgang A Weber, Erika Graf, Michael Mix, Ursula Nestle, Tanja Schimek-Jasch, Rolf Wiehle, Irina Mader, Urs Würtemberger, Karl-Josef Langen, Maximilian Niyazi, Frank Paulsen, Liane König, Frank Anton Giordano, Irina Spehl, Denise Bernhardt, Markus M Schymalla, Christoph Pöttgen, Sabine Semrau, Thomas Brunner, Beatrix Hültenschmidt, Bernd Joachim Krause, Ilja Frank Ciernik, Jürgen Beck, Brigitta G Baumert, Philipp T Meyer, Horst Urbach, Ilinca Popp, GLIAA Study Group, Claus Belka, Franziska Eckert, Michael J. Eble, Elena Sperk, Felix Momm, Stephanie E. Combs, Benedikt Wiestler, Rita Engenhart-Cabillic, Martin Stuschke, Rainer Fietkau, Stephan Nadji, Guido Hildebrandt, Arnab Chakravarti, Susan C. Short, Carsten Nieder, Sabine Schneider-Fuchs, Marco Prinz
| Article suivant Article suivant
  • Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study
  • Caineng Cao, Eric J Sherman, Nadeem Riaz, Sean M McBride, Yao Yu, Achraf Shamseddine, Winston Wong, Lara A Dunn, Alan L Ho, Richard J Wong, Nancy Y Lee

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.